Critical Contrast: GT Biopharma (NASDAQ:GTBP) versus Cogent Biosciences (NASDAQ:COGT)

Cogent Biosciences (NASDAQ:COGT) and GT Biopharma (NASDAQ:GTBP) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, institutional ownership, earnings, risk and valuation.

Profitability

This table compares Cogent Biosciences and GT Biopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-143.09%	-66.96%
GT Biopharma	N/A	N/A	-116.67%

Analyst Recommendations

This is a breakdown of current ratings for Cogent Biosciences and GT Biopharma, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1	2	9	2	2.86
GT Biopharma	1	0	0	0	1.00

Cogent Biosciences currently has a consensus target price of $43.45, indicating a potential upside of 20.37%. Given Cogent Biosciences’ stronger consensus rating and higher possible upside, equities analysts clearly believe Cogent Biosciences is more favorable than GT Biopharma.

Institutional & Insider Ownership

8.1% of GT Biopharma shares are held by institutional investors. 7.3% of Cogent Biosciences shares are held by company insiders. Comparatively, 3.4% of GT Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Volatility and Risk

Cogent Biosciences has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500. Comparatively, GT Biopharma has a beta of 1.28, meaning that its share price is 28% more volatile than the S&P 500.

Valuation and Earnings

This table compares Cogent Biosciences and GT Biopharma”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94 million	($2.16)	-16.71
GT Biopharma	N/A	N/A	-$28.35 million	($6.55)	-0.06

Cogent Biosciences is trading at a lower price-to-earnings ratio than GT Biopharma, indicating that it is currently the more affordable of the two stocks.

Summary

Cogent Biosciences beats GT Biopharma on 7 of the 12 factors compared between the two stocks.

About Cogent Biosciences

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

About GT Biopharma

GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 (GTB-3550) TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.